Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Raltitrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS known ✓ | P04818 | 8/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 1.00 |
| ▸ | FOLR2 | P14207 | 1/20 | 1.00 |
| ▸ | FOLR1 | P15328 | 1/20 | 1.00 |
| ▸ | SLC19A1 | P41440 | 1/20 | 1.00 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 1.00 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raltitrexed SCHEMBL12078376 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL29490413 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL13959 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL7438 | 1.00 | TYMS (1.00) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL16583752 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28384446 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL27995440 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28154699 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL21248507 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 | |
| Raltitrexed SCHEMBL28155448 | 0.99 | TYMS (0.98) | TYMSDHFRFOLR2FOLR1SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102038956-A | Tumor nucleus target medicinal vector and application thereof in preparing anti-tumor medicament | UNIV JILIN | 2011-05-04 | — | — | CN | claimed |
| CN-102038957-A | Efficient cell nucleus targeted medicine vector and application thereof to preparing antineoplastic medicines | UNIV JILIN | 2011-05-04 | — | — | CN | claimed |
| US-20210023006-A1 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-01-28 | — | — | US | disclosed |
| EP-3749318-A1 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019157140-A1 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2678359-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | Merrimack Pharmaceuticals, Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012116317-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| CN-102038957-B | Efficient cell nucleus targeted medicine vector and application thereof to preparing antineoplastic medicines | UNIV JILIN | 2012-03-21 | — | — | CN | disclosed |
| CN-102038957-A | Efficient cell nucleus targeted medicine vector and application thereof to preparing antineoplastic medicines | UNIV JILIN | 2011-05-04 | — | — | CN | disclosed |
| CN-1950088-A | Use of carboxypeptidase G for combating antifolate toxicity | PROTHERICS MEDICINES DEV LTD (GB) | 2007-04-18 | — | — | CN | disclosed |
| CN-1686138-A | Raltitrexed emulsion composition | ZHANG WENFANG (CN) | 2005-10-26 | — | — | CN | disclosed |
| EP-1549742-A1 | METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF | Tjötta, Enok (NO) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004055175-A1 | METHOD FOR SELECTION OF COMPOUNDS WHICH INHIBIT CLONAL CELL GROWTH AND USE THEREOF | TJOETTA ENOK (NO) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023006-A1 | GAMMA POLYGLUTAMATED RALTITREXED AND USES THEREOF | GGCT, IFNG, RARG | TYMS 76/4885DHFR 45/4885FOLR2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.